BioCryst Pharmaceuticals (BCRX) announced that it has completed its acquisition of Astria Therapeutics (ATXS) initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema, HAE, and enhances the company’s long-term growth trajectory. The acquisition was completed for an implied transaction value of approximately $700 million, net of Astria’s cash at closing. BioCryst financed the cash portion of the acquisition with cash on hand and approximately $396.6 million drawn from a financing facility with funds managed by Blackstone. In addition, at the closing of the transaction, BioCryst issued approximately 37.3 million shares of its common stock to Astria’s equity holders.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- Astria stockholders vote to approve acquisition by BioCryst
- BioCryst: Sustained Orladeyo Momentum, Disciplined Financials, and Pipeline Upside Support Buy Rating
- BioCryst Updates ORLADEYO Revenue Outlook and Guidance
- BioCryst reports preliminary Q4 ORLADEYO revenue $151M
- BioCryst sees FY26 revenue $635M-$660M